Dyadic expands commercial non-animal dairy pipeline through new strategic development agreement

USA – Dyadic International, a biotechnology company, has announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins.

The agreement further expands Dyadic’s growing food and nutrition pipeline while reinforcing the Company’s strategy of developing recurring revenue opportunities through strategic development partnerships, licensing and commercial participation.

The new program builds on Dyadic’s expanding portfolio of non-animal dairy proteins and enzymes, including the commercial launch of recombinant bovine chymosin through Inzymes ApS and the ongoing development of recombinant bovine alpha-lactalbumin with BRIG BIO.

Together, these programs demonstrate that Dyadic’s proprietary Dapibus precision fermentation platform can repeatedly generate commercially relevant dairy proteins and enzymes addressing multiple food and nutrition markets.

Dapibus is Dyadic’s proprietary precision fermentation platform designed to rapidly develop and manufacture recombinant food proteins and enzymes using established microbial fermentation processes and existing industrial fermentation infrastructure, supporting efficient, scalable and cost-effective production.

The agreement reflects Dyadic’s commercialization strategy of combining strategic development partnerships with commercial participation.

Under the agreement, Dyadic is eligible to receive development and commercial payments, licensing-related revenues and other potential economic participation tied to successful commercialization, creating multiple pathways for future revenue generation.

Demand for animal-free dairy ingredients continues to increase as food manufacturers seek sustainable, high-quality alternatives that deliver the taste, functionality and nutritional performance of conventional dairy ingredients.

The proteins being developed under this agreement is intended for a broad range of food and nutrition applications supporting improved functionality, texture and nutritional performance across next-generation food ingredients.

Together, Dyadic’s expanding portfolio addresses applications ranging from dairy processing to premium nutrition ingredients.

Dyadic believes Dapibus’ combination of rapid development, scalable microbial manufacturing and production efficiency can help food innovators accelerate commercialization while improving manufacturing economics.

Beyond this individual program, the agreement further demonstrates the versatility of the Dapibus platform to efficiently develop commercially relevant dairy proteins while supporting customers from strain development through commercial manufacturing.

Joe Hazelton, President and Chief Operating Officer of Dyadic Applied BioSolutions, said, “Together with the commercialization of recombinant bovine chymosin through our partnership with Inzymes ApS and our ongoing bovine alpha-lactalbumin collaboration with BRIG BIO, we are building a diversified pipeline of precision-fermented dairy proteins and enzymes.

“Dapibus enables us to rapidly develop and efficiently manufacture new food proteins using established microbial fermentation infrastructure, while our commercialization model creates opportunities for development revenue, licensing, commercial participation and future product sales. Each new program further strengthens the Dapibus platform as a repeatable engine for commercial growth.”

The program will now advance through strain optimization, process development and commercial scale-up activities as Dyadic continues expanding its food and nutrition portfolio with strategic partners.

Dyadic believes its expanding commercial pipeline, strategic partnerships and proprietary microbial expression platforms provide multiple pathways for future revenue generation through development agreements, commercial products, licensing, strategic collaborations and commercial manufacturing opportunities.

To receive our email newsletters with the latest news and insights from Africa, the Middle East and around the world, SUBSCRIBE HERE